Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1176 of 6351
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with pemetrexed-platinum chemotherapy as first-line treat…
Phase 3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New cancer drug FH-006 enters human trials for solid tumors
Disease control Recruiting nowEvaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended dose for phase II clinical trials (RP2D), and prelimi…
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Head-to-Head: which pill tames hidradenitis suppurativa best?
Disease control CompletedThis randomized controlled trial compares the efficacy of oral apremilast and oral acitretin in the treatment of moderate-to-severe hidradenitis suppurativa. Seventy eligible adults were randomly assigned to receive either apremilast (30 mg twice daily) or acitretin (25 mg twice …
Phase 4 • Sponsor: Hayat Abad Medical Complex, Peshawar • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New depression pill could lift the fog without lifelong dependence
Symptom relief Recruiting nowX-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Phase 3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
AI heart scan trial aims to sharpen diagnosis of clogged arteries
Diagnosis OngoingPARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative so…
Sponsor: Cleerly, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 13:03 UTC
-
Brain scan breakthrough: new tracer could catch Parkinson's early
Diagnosis CompletedThe main objective of this study is to establish a standardized method for \[18F\] - FD17 PET imaging in α-synucleinopathy patients, and to analyze its physiological distribution in healthy individuals as well as its pathological distribution in α-synucleinopathy patients, includ…
Sponsor: Ruijin Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC
-
Could a smaller surgery be just as safe for early colon cancer?
Disease control Recruiting nowThe aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \>15%, or with macroscopically suspected T1 tumors, by perf…
Sponsor: Meander Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail aims to tame metastatic prostate cancer
Disease control Recruiting nowThe purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 12:48 UTC
-
New trial tests faster radiation for prostate cancer relapse
Disease control Recruiting nowThis is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.
Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo shows promise in shrinking esophageal tumors before surgery
Disease control Recruiting nowThis study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant therapy with adebrelimab combined with platinum-base…
Sponsor: The Second Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Lab-Grown tumor avatars could personalize breast cancer treatment
Disease control Recruiting nowA biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitiv…
Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial
Disease control Recruiting nowThe goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to gr…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New chickenpox vaccine for toddlers shows promise in safety trial
Vaccine Recruiting nowThe purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have nei…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
-
AI-Powered patch could replace ultrasound for heart checkups
Diagnosis Recruiting nowThis prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of …
Sponsor: Peerbridge Health, Inc • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Could a Five-Lesson school program curb juvenile delinquency?
Prevention CompletedThe purpose of this study is to investigate whether the prevention program Kapot Sterk is effective.
Sponsor: Marit van de Mheen • Aim: Prevention
Last updated Jul 16, 2026 00:00 UTC
-
New hope for rare lymphoma: mosunetuzumab trial launches
Disease control Recruiting nowThe purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study w…
Phase 2 • Sponsor: Izidore Lossos, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Sound waves aimed at the brain could ease twisted neck
Symptom relief Recruiting nowThis study is a single-blinded, randomized control study that aims to recruit 48 participants. Participants will be "randomized" into one of the study arms of the study: active stimulation to GPi, active stimulation to DN, or sham stimulation. The purpose of the study is to look …
Sponsor: Robert Chen • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New shot could tame stubborn high blood pressure
Disease control Recruiting nowThis is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hy…
Phase 2 • Sponsor: E-Star BioTech, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody drug aims to tackle kidney disease
Disease control OngoingThis study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous nephropathy, and exploring the Phase III dosing regimen, s…
Phase 2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a common anesthetic help prevent liver cancer from coming back?
Disease control Recruiting nowAccording to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC). The latter currently ranks 16th among the leading cau…
Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC